ProMIS Neurosciences, Inc. (PMN)
3.14
-0.07
(-2.18%)
USD |
NASDAQ |
Nov 18, 15:00
ProMIS Neurosciences Debt to Equity Ratio : 0.00 for Sept. 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.00 |
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.00 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.00 |
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| Date | Value |
|---|---|
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | -1.534 |
| March 31, 2017 | 0.0725 |
| December 31, 2016 | 1.739 |
| September 30, 2016 | 0.1077 |
| June 30, 2016 | 0.3034 |
| March 31, 2016 | 0.1826 |
| December 31, 2015 | 0.197 |
| September 30, 2015 | 0.1002 |
| June 30, 2015 | -0.1117 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Edesa Biotech, Inc. | 0.00 |
| Oncolytics Biotech, Inc. | -0.0546 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6888 |
| Anixa Biosciences, Inc. | 0.012 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 47.16M |
| Total Liabilities (Quarterly) | 5.399M |
| Shareholders Equity (Quarterly) | 41.76M |
| Current Ratio | 8.827 |